Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: Daniel who wrote (895)	11/8/1999 9:25:00 AM
From: Beltropolis Boy	Respond to of 947

Misonix Announces Fiscal First Quarter of 2000 Results; Reports Increased Sales of 17% November 8, 1999 08:07 AM FARMINGDALE, N.Y.--(BUSINESS WIRE)--Nov. 8, 1999--MISONIX, INC. (MSON) today reported results for its first fiscal quarter of 2000 ended September 30, 1999. Revenues increased 17% for the fiscal first quarter of 2000 to $6.5 million compared to $5.6 million for the same period of fiscal 1999. The Company reported net income of $600,000 or $0.09 per diluted share for the quarter compared to a loss of $300,000 or $0.05 for the fiscal first quarter of 1999. Last year's results included a bad debt charge of $1.7 million. The Company stated that growth in medical products and shipments of the Mystaire(TM) air pollution control system contributed to the increase in revenues despite reduced revenues in industrial ultrasonic products and fume enclosures. The increase in shipments of Mystaire's air pollution control products resulted from a major contract that was awarded in fiscal 1999. In addition, Misonix received product development revenue of approximately $150,000 from the previously announced joint development agreement with Focus Surgery, Inc. Michael A. McManus, Jr., President and Chief Executive Officer stated, "We are very pleased with recent developments which illustrate our progress in attaining our stated goals. Following the court decision in our favor in the patent dispute with Mentor Corp., we filed a petition to regain the inventory of soft tissue aspirators that we sold to Medical Device Alliances (MDA) and commenced negotiations toward the establishment of a new license agreement. To that end, we have signed the Letter of Intent with MDA announced on October 22nd which is under review by the court." "In another very important development, we announced that we completed the agreement to invest in 7% of the capital stock of Hearing Innovations, Inc. Hearing Innovations has developed HiSonic(R), the ultrasonic bone conduction device that is being used to help the profoundly deaf to hear. They are also developing and testing a device that may help people with ringing in the ear (tinnitus). In the U.S., 20 million people suffer from these afflictions. Misonix has the option to increase its investment to 15% and obtain the manufacturing rights to HiSonic(R) and the sales and marketing rights for the tinnitus product." Mr. McManus continued, "During Prostate Cancer Awareness Week in September, we released an update of our progress on the Sonoblate(TM) (SBX), Focus Surgery's non-invasive, high intensity focused ultrasound treatment for benign prostatic hyperplasia (BPH) or enlarged prostate. We are presently in Phase III clinical trials in the U.S. and are particularly excited by the prospects for the Sonoblate(TM) especially since the potential market is so large - approximately eight million men in the U.S. alone have BPH." "Looking ahead, we are continuing to invest in research and development to develop the next generation ultrasonic bone cutter and dermabrasion products. We have also invested in an expanded sales force for our ultrasonic products and fume enclosures to ensure that we maximize our opportunities in these markets. We are convinced that with each milestone we surpass, we are laying the groundwork for a solid future for each of our product lines and hence, our shareholders."

To: Daniel who wrote (895)	11/16/1999 10:10:00 AM
From: Beltropolis Boy	Respond to of 947

so, is the yooveeaay guy the last one left holding the (empty) bag, dan? is the party over? should i shut off the lights on my way out? OT: how many tech students does it take to change a tire? one, but s/he gets three credits for it. how many uva students does it take? two: one to hold the drinks and the other to call his old man. ----- Misonix Announces Acquisition of 51% Stake in Sonora Medical Systems; Company Continues Its Expansion in Ultrasound Technologies November 16, 1999 09:28 AM FARMINGDALE, N.Y.--(BUSINESS WIRE)--November 16, 1999--MISONIX, INC. (MSON) today announced it has acquired a 51% stake in Acoustic Marketing Research Inc. doing business as Sonora Medical Systems, Inc. for $1.35 million. The agreement includes an option for Misonix to increase its investment by 39% under certain circumstances. Sonora Medical Systems (Sonora), located in Longmont, Colorado is an ISO 9002 certified refurbisher of high-performance ultrasound systems and replacement transducers for the medical diagnostic ultrasound industry. Sonora also offers a full range of aftermarket products and services such as its own ultrasound probes and transducers, and other services that can extend the useful life of their customers' ultrasound imaging systems beyond the usual five to seven years. As reported in numerous articles published in the Wall Street Journal, Second Source and Modern Healthcare and Diagnostic Imaging, the market for reconditioned/refurbished medical imaging equipment continues to increase and is expected to expand to approximately $1.5 billion by 2004. Commenting on the acquisition, Michael A. McManus, Jr., President and Chief Executive Officer said, "There are many synergies in this acquisition for both Sonora and Misonix. Both companies bring a significant depth of ultrasound technology knowledge to the table as well as an abundance of manufacturing expertise. The investment fits in perfectly with our plan to become a dominant ultrasound technology provider for the medical community, giving us a presence in five significant medical markets: medical imaging, enlarged prostate treatment, alleviation of hearing disorders, ultrasound surgical blades and soft tissue aspirators. We are pleased that the principal executives, G. Wayne Moore and Bill Phillips, will be an integral part of Sonora's future success and important members of the Misonix executive team." Mr. McManus continued, "Our investment will be utilized directly to expand Sonora's capabilities by acquiring additional inventory for current expansion, increasing research and development efforts on additional product offerings and expanding its present interactive internet sales capabilities. These steps are designed to compound increasing revenues over the next several years. Revenues for the nine months ended September 1999 were $1.7 million and we expect that the infusion of capital from Misonix will help Sonora reach our rapid growth expectations. As an example of its technical capability, Sonora has been chosen as a subcontractor to Cassling Diagnostic Imaging (CDI) to help develop a 3-D fetal imaging device in concert with an Israeli company called Biomedicom through the BIRD foundation, a US Industrial-Israeli Research and Development Foundation. Sonora is expected to receive approximately $0.3 million per year for the next two years from this development effort." Mr. G. Wayne Moore, founder and Chief Executive Officer of Sonora added, "All of our products and services are focused on both reducing the initial cost of an ultrasound system and extending the system's useful life through upgrades and cost-effective repairs. We also offer very high quality, proprietary products with more features than otherwise available and that cost significantly less. In this era of managed care and tightly controlled costs, Sonora Medical has a very important marketing advantage in its ability to reduce the cost for medical imaging equipment, parts and accessories. This is especially important when you realize that over 70% of the costs of the system come after the initial purchase. We are convinced that the combined resources of Misonix and Sonora should serve to create an even more powerful competitive force and we look forward to a highly rewarding relationship for all parties." Mr. Bill Phillips, Chief Technical Officer of Sonora stated "We are pleased to join such a strong financial partner as Misonix as we continue to develop new products and services focused on lowering healthcare costs without sacrificing the quality of patient care." In the most recent quarter ended September 30, 1999, Misonix reported revenue of $6.5 million and net income of $605,000 or $0.09 per diluted share with a strong balance sheet. Misonix, Inc. develops, manufactures, and markets medical, scientific, and industrial ultrasonic and air pollution control systems. Sonora Medical Systems offers an array of high quality, previously owned and refurbished medical imaging systems to healthcare providers worldwide. Sonora utilizes a modern ESD controlled, ISO 9002 and GMP certified manufacturing complex in which new and previously owned ultrasound systems are configured and clinically tested. Visit Sonora's web site at 4sonora.com.

To: Daniel who wrote (895)	1/26/2000 11:39:00 AM
From: Beltropolis Boy	Read Replies (3) \| Respond to of 947

dancing with myself? ----- Misonix Announces Results for Second Fiscal Quarter 2000 January 26, 2000 09:48 AM FARMINGDALE, N.Y.--(BUSINESS WIRE)--Jan. 26, 2000--Revenues Increase 24%; Net Income Improves by 53% MISONIX, INC. (MSON) today reported results for its second fiscal quarter of 2000 ended December 31, 1999. Revenues increased 24% to $7.3 million compared to $5.9 million for the same period in fiscal 1999. Net income improved 53% to $711,000 or $0.11 per diluted share for the second fiscal quarter of 2000 compared to $465,000 or $0.07 per diluted share for the second quarter of fiscal 1999. Revenues for the six months ended December 31, 1999 were $13.8 million, a 21% increase over $11.4 million reported in the same period ended December 31, 1998. The Company reported net income for the six months of $1.3 million or $0.20 per diluted share compared to $185,000 or $0.03 per diluted share for the same period in 1998, a 600% improvement. The Company stated that sales for the quarter increased due to the revenue from sales of its soft tissue aspirator product, the inclusion of revenue for paid research and development from Focus Surgery and the consolidation of revenues from Sonora Medical Systems (Sonora). Higher industrial ultrasonic and Labcaire revenues were partially offset by lower revenue from fume enclosure products and reduced shipments to U.S. Surgical. Orders from U.S. Surgical remain in tact, but the timing for future deliveries of product has been changed at U.S. Surgical's request. Michael A. McManus, Jr., President and Chief Executive Officer of Misonix, stated, "We continue to be pleased with the Company's financial results of revenue and earnings growth in the first half of the year. We look forward to the benefits to be derived from other initiatives that were implemented recently including our equity investments in Hearing Innovations, Focus Surgery and Sonora Medical." During the second quarter of this year, Misonix signed an agreement with Hearing Innovations to help launch the HiSonic(R), a non-invasive hearing device that enables the profoundly deaf to hear at a relatively low cost compared to a product in the marketplace at this time which requires major surgery. A pilot program has been launched to test the HiSonic(R) in three doctors' offices in New York, Miami and Tucson. Earlier this year, Misonix purchased a 20% equity position in Focus Surgery, Inc., a privately-held Indianapolis firm specializing in ultrasound technology for the non-invasive treatment of benign prostatic hyperplasia (BPH), more commonly known as enlarged prostate. The high intensity focused ultrasound (HIFU) device is in Phase III PMA clinical trials in the U.S., but has already been used successfully on 1,500 patients primarily in the Far East. Phase III trials in the U.S. should be completed by the fall of 2000. The Company estimates that approximately eight million men have BPH and over $4.5 billion a year is spent on its treatment in the U.S. The worldwide market is estimated to be $8 billion. Mr. McManus continued, "In an important development, we have completed the acquisition of our 51% stake in Sonora announced in November 1999. Sonora is a 9002 certified refurbisher of high performance ultrasound systems and replacement transducers for the medical diagnostic ultrasound industry. Sonora also has tremendous technical abilities as evidenced by its work with 3-D imagery which is anticipated to have many clinical uses. We expect Sonora to contribute to our technological expertise and to both the short- and long-term financial growth of Misonix." Mr. Mc Manus concluded, "We continue to negotiate for a long term license agreement with Medical Device Alliance/LySonix to market and sell our soft tissue aspirator product. The attainment of our goal to team up with Medical Device Alliance/Lysonix, combined with the many other initiatives we have taken over the past year, should increase value for the Company's shareholders."